Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 17/20 | 0.49 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7459610 | 0.93 | KCNN4 (0.43) | RXRAKCNN4POLB | |
| SCHEMBL7464760 | 0.84 | KCNN4 (0.42) | KCNN4POLB | |
| SCHEMBL7460353 | 0.84 | GSK3A (0.48) | RXRAKCNN4POLB | |
| SCHEMBL7466491 | 0.84 | POLB (0.43) | RXRAKCNN4POLB | |
| SCHEMBL7468575 | 0.83 | KMT2A (0.46) | RXRAPOLB | |
| SCHEMBL7459835 | 0.83 | KCNN4 (0.42) | KCNN4POLB | |
| SCHEMBL5485145 | 0.82 | RXRA (0.46) | RXRAPOLB | |
| SCHEMBL5491294 | 0.82 | KCNN4 (0.43) | RXRAKCNN4POLB | |
| SCHEMBL7461597 | 0.82 | KCNN4 (0.41) | RXRAKCNN4 | |
| SCHEMBL7463442 | 0.81 | ALDH1A1 (0.46) | RXRAKCNN4POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7226940-B2 | Substituted heterocycles for the treatment of diabetes and other diseases | INCYTE SAN DIEGO, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-20060004059-A1 | Substituted heterocycles for the treatment of diabetes and other diseases | PFAHL MAGNUS | 2006-01-05 | — | — | US | disclosed |
| US-6515003-B1 | Useful in the treatment of diseases related to lipid and carbohydrate metabolism | MAXIA PHARMACEUTICALS, INC. | 2003-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004059-A1 | Substituted heterocycles for the treatment of diabetes and other diseases | FABP4, HPGDS, GPR119 | RXRA 307/4885KCNN4 4620/4885POLB 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.